Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

Table 1

Demographic data, rating scale scores, and clinical neurootological findings at enrollment; means ± standard deviations or numbers/percentages; 𝑃 values (Wilcoxon test and Fisher's exact test∗).

	EGb 761	Betahistine	𝑃 value
Gender
Male	25/31%	22/27%	0.603∗
Female	55/69%	58/73%
Age [years]	57.5±9.2	57.9±8.4	0.561
Body mass index [kg/m^2]	27.0±4.2	28.3±4.2	0.082
Duration of symptoms [months]	25.1±37.3	22.5±31.2	0.633
NAS	5.4±1.4	5.2±1.2	0.644
VSS-SF total score	24.2±8.9	22.6±8.5	0.239
VSS-V subscore	10.6±5.5	9.9±5.4	0.433
VSS-A subscore	13.5±5.6	12.6±4.9	0.447
SDS total score	15.2±5.4	14.2±5.4	0.263
Spontaneous nystagmus	42/52.5%	44/55%	0.874
Romberg test
No swaying	2/2.5%	5/6.3%	0.447
Slight swaying	66/82.5%	68/85.0%
Swaying/foot movement	11/13.8%	6/7.5%
Tendency to fall	1/1.3%	1/1.3%
Unterberger's stepping test
Rotation <30°	45/56.3%	46/57.5%	1.000
Rotation 30°–60°	32/40.0%	32/40.0%
Rotation >60°	3/3.8%	2/2.5%